Link to: Obesity and Overweight
Overweight and Obesity
Overweight and obesity have significant health impact and their increase over the last several years has been likened to an epidemic. Currently, some 42% of the US population has obesity and an additional one-third is classified as overweight. Cost-effective and tolerable long-term therapies are urgently required.
Link to: Irritable Bowel Syndrome
The IBS Challenge: A Critical Unmet Need
IBS affects 6%-12% of people, disrupting daily life with chronic pain and digestive distress. Despite its impact, no FDA-approved treatment exists for severe acute IBS pain, leaving patients with limited options.
ROSE-010 offers a breakthrough solution—a fast-acting, on-demand GLP-1 therapy designed to provide rapid relief from severe IBS pain when it matters most. A new, targeted approach to improving quality of life.
Link to: Science
Science
The Science Behind ROSE-010: IBS Acute Pain Treatment & Obesity and Appetite Control.
Rose Pharma is committed to advancing ROSE-010 as a pioneering therapy for IBS pain and weight management. With multiple clinical trials underway, the future of on-demand GLP-1 therapy is within reach. Stay tuned for updates on our ongoing clinical programs.